The global antibody production market size was valued at USD 16.35 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.92% from 2023 to 2030. Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, coupled with the growing demand for therapeutic antibodies, has led to the rapid growth of the market. The COVID-19 pandemic has had a significant impact on the market. With the urgent need for therapeutic antibodies and vaccines to combat the virus, there has been a surge in demand for antibody production services.
However, disruptions in the global supply chain and manufacturing processes caused by lockdowns, travel restrictions, and workforce shortages have posed significant challenges to the market's growth. Despite the challenges, the market has demonstrated resilience, and many companies have adapted their operations to continue serving customers during the pandemic. In October 2020, Ely Lily announced an agreement to provide a potential COVID-19 antibody treatment to nations with low and middle income. This COVID-19 Therapeutics Accelerator initiative was established by the Gates Foundation, Wellcome, and Mastercard to hasten the creation and availability of therapies for COVID-19, including this endeavor to ensure the fair availability of innovative treatments.
According to estimates published by the American Cancer Society, 1.9 million new cancer cases were expected to be diagnosed in the United States alone in 2022, resulting in 609,360 cancer deaths. Moreover, it is projected that there will be 28.0 million new cancer cases and 16.2 million cancer deaths worldwide by 2040. The increasing incidence of cancer has led to the growing demand for cancer therapeutics such as monoclonal antibodies. These antibodies are artificially produced to target specific cancer cells, and they have become a crucial tool in cancer treatment. The rising demand for antibody-based drugs, is expected to drive the growth of the antibody production industry.
Increasing investment in research and development of monoclonal antibodies is expected to drive market growth, especially in cancer treatment, which accounts for almost 50% of all R&D programs related to mAbs. The targeted approach of mAbs has revolutionized cancer treatment by reducing side effects and improving patient outcomes. Despite this, ongoing research and development are necessary to optimize mAb efficacy in cancer treatment. A significant milestone in the field of mAb therapeutics is the recent approval, by the European Commission of Bristol Myers Squibb’s combination therapy of Yervoy and OPDIVO for treating malignant pleural mesothelioma in June 2021. This approval highlights the potential of mAbs in treating complex and severe diseases and reinforces the need for continued investment in the research and development of mAb therapeutics.
In 2022, the consumables segment dominated the market with a market share of 55.93% and is estimated to have the highest CAGR during the forecast period. Consumables include a wide range of products such as reagents, kits, media, buffers, and other materials that are used in the production of antibodies. The increasing demand for antibodies for research, diagnostics, and therapeutics has led to a corresponding rise in the demand for consumables. In addition, the increasing adoption of automated systems for antibody production has also contributed to the growth of the consumables segment.
The instruments segment is expected to experience lucrative growth in the global market in the coming years. Instruments are an essential component of antibody production and include a wide range of equipment such as bioreactors, centrifuges, chromatography systems, and other devices used in the production process. In June 2022, Evonik launched a new peptide cQrex AC would provide highly soluble and chemically defined source of L-cystine that facilitates the efficient supply of this crucial amino acid to cells. Thus, this product would offer an adequate amount of L-cystine, which is essential for various biological processes in the body, henceforth, to propel the production of cell-culture-based antibody production.
The downstream segment dominated the market in 2022 with a market share of 67.04% and is anticipated to expand with the faster CAGR of 13.48% from 2023 to 2030. The process is involved in ensuring the quality, safety, efficacy, purity, and identity of antibodies. In addition, various technological advancements support the downstream process to maintain efficiency, thus, fueling innovations in bio-manufacturing. The latest advancements in processing include single-use sensors, membrane chromatography technology, remote monitoring, and the use of data analytics. For instance, in March 2019, GE Healthcare partnered with Amgen to establish a digital data exchange collaboration program to understand the advances in the bio-manufacturing process on various raw material variability.
The upstream process segment is projected to have a lucrative growth in the market over the forecast period. This is attributed to various advancements and investments made in production infrastructure by several manufacturers. Major manufacturers are using cutting-edge bioreactors for the upstream process to provide superior quality of end-product. For instance, On April 18, 2023, Cytiva (part of Danaher), launched the X-platform single-use bioreactors. The new platform is designed to increase process efficiency in upstream bioprocessing operations. The X-platform can be used for the production of cell and gene therapies, protein-based drugs including monoclonal antibodies, as well as viral vectors.
The monoclonal antibody segment is anticipated to dominate the antibody production market with a revenue share of 63.25% in 2022 and is expected to have the higher CAGR of 13.58% during 2023-2030. The growth of the segment is reported due to increasing investments in research on monoclonal antibodies as well as the various novel launch of antibody-based products. For instance, in March 2023, Eli Lilly, a US-based pharmaceutical company has invested nearly USD 1 billion for a monoclonal antibody (mAbs) manufacturing plant in Ireland that would start the production of novel clinical products by the 2026.
The polyclonal antibody segment is projected to show a significant growth over the forecast period, owing to various benefits such as smooth production process, accessible at low cost, growing diagnostic test for increasing prevalence diseases.Furthermore, the development of new technologies and techniques for polyclonal antibody production, such as recombinant DNA technology and transgenic animal models, is expected to further boost the growth of this segment. Moreover, polyclonal antibodies can be produced more rapidly and cost-effectively than monoclonal antibodies, as they do not require the complex cell culture and screening processes involved in monoclonal antibody production.
The pharmaceutical and biotechnology companies dominated the antibody production industry with a revenue share of 55.06% in 2022. One of the key factors that are contributing to the growth of the segment is the increasing applications of biopharmaceutical companies in the production of antibodies. Pharmaceutical and biotechnology companies have been at the forefront of the market, with many of the leading companies investing heavily in research and development activities. These companies have access to significant financial resources and cutting-edge technologies, which allow them to develop innovative products that meet the evolving needs of healthcare providers and patients. For instance, Roche, a Swiss multinational healthcare company, is one of the leading players in the market, with a wide range of antibody-based products in its portfolio. The company's products are used in the diagnosis and treatment of various diseases such as cancer, autoimmune disorders, and infectious diseases.
The CROs and CDMOs segment held the highest CAGR of 13.68% during 2023-2030. This is primarily due to the increasing demand for outsourcing services from pharmaceutical and biotechnology companies, which are seeking to reduce their operational costs and increase their focus on core competencies. Furthermore, the COVID-19 pandemic has further increased the demand for outsourcing services from CMOs and CROs, as many companies are seeking to rapidly develop and manufacture antibody-based treatments and vaccines for the disease.
In 2022, North America held the largest revenue share at 38.29% for the antibody production market, owing to the presence of key biopharmaceutical and biotechnology companies in the U.S. and Canada. Moreover, the growing investments for drug discovery and rising advancements in research, as well as healthcare infrastructure drive the growth of the market across the region. Additionally, the adoption of biopharmaceuticals is on the rise in North America, which is driving the demand for antibody production. Biopharmaceuticals are becoming increasingly popular due to their specificity, efficacy, and safety, and antibodies are a type of biopharmaceutical that are being used to treat various diseases. Furthermore, according to a published article by the American Chemical Society in February 2023, pharmaceutical companies are making significant investments in developing their technology such as AI technology that would help in accelerating the speed of the drug development process, thus, reducing the cost of discovering new drugs to the market.
Asia Pacific is projected to expand with the fastest CAGR of 16.14% from 2023 to 2030, owing to the untapped opportunities in this region. Factors such as increasing investment in research and development activities, growing demand for therapeutics and diagnostics, and a rising aging population drive the growth of the market. Moreover, the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases is driving the demand for antibody-based therapies and diagnostics.
The high demand for antibody production for multiple applications has led to numerous market opportunities for major players to capitalize on. Key players are involved in strategic initiatives such as mergers, acquisitions, and collaborations to maximize their market share. For instance, in February 2023, Thermo Fisher Scientific, Inc. announced its collaboration with Elektrofi to support manufacturing capabilities for upcoming clinical trials of biologics such as therapeutic proteins, monoclonal antibodies, and other large molecule drugs. Thus, these collaborations among players are anticipated to propel the growth of the market during the forecast period. Some of the prominent players in the global antibody production market include:
Thermo Fisher Scientific, Inc.
Pacific Biosciences of California, Inc.
ProPhase Labs, Inc. (Nebula Genomics)
Azenta US, Inc.
Market size value in 2023
USD 18.31 billion
Revenue forecast in 2030
USD 42.86 billion
CAGR of 12.92% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, process, type, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI, QIAGEN, Agilent Technologies, PerkinElmer, Inc., ProPhase Labs, Inc., Psomagen, Azenta US, Inc..
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global antibody production market report on the basis of product, process, type, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Buffers and Reagents
Chromatography Resins and Columns
Filtration Consumables and Accessories
Process Outlook (Revenue, USD Million, 2018 - 2030)
Type Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical and Biotechnology Companies
CROs and CDMOs
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global antibody production market size was valued at USD 16.35 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.92% from 2023 to 2030
b. The global antibody production market is expected to grow at a compound annual growth rate of 12.92% from 2023 to 2030 to reach USD 42.86 billion by 2030.
b. Downstream processing dominated the antibody production market with a share of 67.04% in 2022. This is attributable various technological advancements supporting the downstream process to maintain efficiency, thus, fueling innovations in bio-manufacturing, and hence, increasing the demand for the process in the antibody production market.
b. Some of the key players operating in the antibody production market include Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI, QIAGEN, Agilent Technologies, PerkinElmer, Inc., ProPhase Labs, Inc. (Nebula Genomics), Psomagen, Azenta US, Inc.
b. Major factors driving market growth include the rising incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, as well as the increased need for therapeutic antibodies the antibody production market is anticipated a significant growth.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."